






















Ourofino Saúde Animal  
JPM Check-up – 23rd of August


# 29 Year History




# What we do

## A veterinary pharmaceutical company


		% of net revenues	Production animals	Companion animals	International operations	Selected products
Products per Category	Vaccines	 9.7%	4	-	Ouro Fino currently exports to 14 countries throughout the world	  Ourovac Aftosa    Ourovac Clostridium
	Antiparasitics	 40.0%	24	4		  Colosso FC30    Master LP
	Antibiotics	20.3% 	20	6		  Ciprolac    Doxifin PS
	Therapeutic	16.6% 	16	13		  Sincrocio    Dermotrat
	Nutritional	3.1% 	9	9		  Enragold    Ractosuín
	Others	10.3% 	13	1		  Herbalvet    MaxicamGel
% of net revenues (2015)			81%	12%	7%	
# of products from current portfolio 2015			86	33		



 **Global (US\$ bn) – 2014E**



 **Brazil (R\$ mm)**



## Highlights


### Brazil as the 3<sup>rd</sup> largest market with strong growth opportunities

**Major animal protein producer**

**Still incipient in the use of animal health products**

**Growing need to improve animal productivity as a key driver of demand for animal health products**





# Leading Position and Proven Ability to Gain Market Share

Ouro Fino plays a key role in the animal health market, being the largest local player


## Highlights

### Closer relationship with clients

- Direct sale to resellers in production animals
- Technical sales and educational programs

### Customization via molecule combination and application methods


## Brazilian Animal Health Ranking<sup>1</sup>




# Financial Highlights




Consolidated net revenues (R\$mm)




Gross profit (R\$mm) and margin




SG&A (R\$mm) percentage on net revenue



EBITDA (R\$mm) and margin



Net profit (R\$mm) and margin









# Thank you

**OFSA3 IR Team – e-mail: [ri@ourofino.com](mailto:ri@ourofino.com)  
website: [ir.ourofino.com](http://ir.ourofino.com)**